# US 2021/0283056 A1 · Compositions for therapeutics prescreening

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0283056 A1
- Document ID: US20210283056A1
- Status: Published application
- Kind: A1
- Application number: 17/257,932
- Filed: 2019-07-04
- Published: 2021-09-16
- Earliest claimed: 2018-07-05
- Assignees: Barcode Diagnostics Ltd.
- Applicants: Barcode Diagnostics Ltd.
- Inventors: Ronen EAVRI; Annie SABBAH; Felix BADINTER; Raphael TSHUVA; Avi SCHROEDER
- Web page: https://patentgrep.com/patent/US20210283056A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6851: Quantitative amplification
- C12Q 1/6869: Methods for sequencing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is provided. Methods of predicting a response of a subject to a therapeutic agent using the composition, as well as methods of producing the composition are also provided.

## Claims

### Claim 1

A composition comprising a plurality of types of carriers, each type of carrier independently comprising at least a single-cell lethal amount of at least one therapeutic agent and at least one barcode uniquely identifying said at least one therapeutic agent, wherein said composition comprises a substantially equal number of each type of carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein each type of carrier comprises a substantially equal barcode concentration.

### Claim 3 (depends on 1)

The composition of claim 1, wherein each type of carrier comprises a substantially equal concentration of said at least one therapeutic agent relative to an effective therapeutic dose (ETD) of said at least one therapeutic agent.

### Claim 4 (depends on 1)

The composition of claim 1, wherein each type of carrier comprises a different at least one therapeutic agent.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said carrier is a liposome, and each type of liposome comprises a substantially equal size and a substantially equal lipid concentration.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said substantially equal lipid concentration comprises a variance of at most 1%, wherein said lipid concentration is between 30-55 mM or both.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein said concentration of said at least one therapeutic agent is not more than 2% of said ETD of said at least one therapeutic agent.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said substantially equal concentration of said at least one therapeutic agent relative to said ETD of said at least one therapeutic agent comprises a variance of not more than 1% of said ETD.

### Claim 10 (depends on 1)

The composition of claim 1, comprising at least 3 types of carriers.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method for predicting the response of a subject afflicted with a disease to at least one therapeutic agent, the method comprising the steps of:
(a) administering to the subject the composition of claim 1;
(b) obtaining a sample from said subject; and
(c) identifying, in said sample, the efficacy of said at least one therapeutic agent by the presence of said unique barcode;
thereby predicting the response of a subject afflicted with a disease to a therapeutic agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein said sample comprises cells from said subject.

### Claim 16 (depends on 14)

The method of claim 14, wherein said sample is a biological fluid sample containing cell free DNA (cfDNA).

### Claim 17 (depends on 14)

The method of claim 14, wherein said disease is cancer.

### Claim 18 (depends on 14)

The method of claim 14, wherein said administration is intravenous injection and said composition comprises 1-200 of each type of carrier per a single disease cell of said subject.

### Claim 19 (depends on 14)

The method of claim 14, wherein said administration is intratumoral injection, and said composition comprises 1-20 of each type of carrier per a single disease cell of said subject.

### Claim 20 (depends on 14)

The method of claim 14, wherein said obtaining is performed within a time frame of 48-192 hours following administration of said composition.

### Claim 21 (depends on 14)

The method of claim 14, wherein said barcode is a nucleic acid molecule and said identifying comprises sequencing said nucleic acid molecule.

### Claim 22 (depends on 14)

The method of claim 14, wherein said barcode is a nucleic acid molecule and wherein said identifying comprises amplifying said nucleic acid molecule.

### Claim 23 (depends on 1)

A method of producing the composition of claim 1, the method comprising:
(a) generating a plurality of solutions, each solution comprising a type of carriers, each type of carrier independently comprising at least a single-cell lethal amount of at least one therapeutic agent and at least one barcode uniquely identifying said at least one therapeutic agent;
(b) measuring the concentration of molecules of said type of carriers in said each solution;
(c) mixing together substantially equal numbers of molecules of each type of carrier; thereby producing the composition of claim 1.

### Claim 24 (depends on 23)

The method of claim 23, further comprising measuring the concentration of said therapeutic agent in said each solution and wherein said mixing together comprises mixing together substantially equal concentrations of said at least one therapeutic agent relative to an effective therapeutic dose (ETD) of said at least one therapeutic agent.
